i 
MINUTES OF MEETING - March 6-7 27 
XIX. PROPOSAL TO INCLUDE SACCHAROMYCES CEREVISIAE UNDER SECTION III-O OF THE 
GUIDELINES ~ 
Dr. Setlow said she had drafted a proposal (tab 855) to include Sacchar- 
cmyces cerevisiae laboratory strains under Section III-O of the Guide- 
lines. She said additional information concerning yeast has been obtained, 
including information that Saccharcmyces cerevisiae is unable to express 
higher eukaryotic genes. She said sne believed that seme of the arguments 
advanced earlier in support of HV1 certification for Saccharomyces cere- 
visiae could also be advanced to support the inclusion of Saccharomyces 
cerevisiae under Section III-O. She asked for comments concerning this 
proposal. 
Dr. Gottesman said that the basic characteristics of the Saccharomyces 
cerevisiae HV systems should be reviewed by the RAC. Dr. Baltimore said 
that laboratory Saccharcmyces cerevisiae strains are as enfeebled as 
Escherichia coli K-l2. 
Dr. Gottesman questioned whether the stipulation in Section III-O that 
any deliberate attenpt to express a eukaryotic protein product must be 
reviewed by the local IBC is sufficient review for experiments using yeast 
HV systems. Dr. Goldstein said the implications of an Saccharcmyces 
cerevisiae system expressing eukaryotic proteins should be examined in 
greater depth. 
Dr. Young suggested that the data indicating that Saccharcmyces cerevisiae 
systems do not express higher eukaryotic proteins be published in the 
Recombinant ENA Technical Bulletin . Dr. Goldstein agreed. Dr. Setlow 
said she would ask the investigators if they would publish this data in 
the Bulletin . Proposed language including Saccharomyces cerevisiae 
under Section III-O of the Guidelines will be published in the Federal 
Register prior to the next meeting. 
XX. REPORT OF VISIT TO ELI LILLY AND COMPANY 
Dr. Walters reported on the visit of January 28, 1980, which he, Dr. Emmett 
Barkley, Mr. Ray Thornton, and Dr. Robert McKinney had made to the Eli Lilly 
plant in Indianapolis, Indiana. Dr. Parkinson asked about Dr. McKinney's 
background. Dr. McKinney said that he has consulted for the NIH Office of 
Research Safety for four and one-half years. He possesses a degree in 
epidemiology with a virology specialty. He had worked at the bench for 
over 20 years, including 10 years at Fort Detrick where he was a member 
of the Safety Committee, and had much experience in the design of biolo- 
gical containment facilities. 
[ 62 ] 
